DE68927188T2 - Antikörper, spezifisch gegen elam-1 sowie deren verwendung - Google Patents

Antikörper, spezifisch gegen elam-1 sowie deren verwendung

Info

Publication number
DE68927188T2
DE68927188T2 DE68927188T DE68927188T DE68927188T2 DE 68927188 T2 DE68927188 T2 DE 68927188T2 DE 68927188 T DE68927188 T DE 68927188T DE 68927188 T DE68927188 T DE 68927188T DE 68927188 T2 DE68927188 T2 DE 68927188T2
Authority
DE
Germany
Prior art keywords
elam
expression
detecting
specific
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68927188T
Other languages
English (en)
Other versions
DE68927188D1 (de
Inventor
Michael Bevilacqua
Michael Gimbrone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23033111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68927188(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Application granted granted Critical
Publication of DE68927188D1 publication Critical patent/DE68927188D1/de
Publication of DE68927188T2 publication Critical patent/DE68927188T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE68927188T 1988-11-14 1989-11-14 Antikörper, spezifisch gegen elam-1 sowie deren verwendung Expired - Fee Related DE68927188T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27086088A 1988-11-14 1988-11-14
PCT/US1989/005075 WO1990005539A1 (en) 1988-11-14 1989-11-14 Antibodies specific for elam-1 and the use thereof

Publications (2)

Publication Number Publication Date
DE68927188D1 DE68927188D1 (de) 1996-10-17
DE68927188T2 true DE68927188T2 (de) 1997-04-24

Family

ID=23033111

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68927188T Expired - Fee Related DE68927188T2 (de) 1988-11-14 1989-11-14 Antikörper, spezifisch gegen elam-1 sowie deren verwendung

Country Status (8)

Country Link
US (1) US5403713A (de)
EP (1) EP0534944B1 (de)
JP (1) JPH04501565A (de)
AT (1) ATE142505T1 (de)
AU (1) AU636589B2 (de)
CA (1) CA2002860A1 (de)
DE (1) DE68927188T2 (de)
WO (1) WO1990005539A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
EP0408859B1 (de) * 1989-05-23 1995-08-09 Otsuka Pharmaceutical Co., Ltd. Monoklonale Antikörper gegen aktivierte endotheliale Zellen
WO1992008489A1 (en) * 1990-11-08 1992-05-29 Biogen, Inc. Treatment for inflammatory bowel disease
IE914075A1 (en) * 1990-11-23 1992-06-03 Gen Hospital Corp Inhibition of cell adhesion protein-carbohydrate¹interactions
EP0568631A4 (de) * 1991-01-24 1995-04-05 Cytel Corp Monoklonale antikörper gegen elam-1 und deren verwendungen.
AU667813B2 (en) * 1991-05-03 1996-04-18 Rockefeller University, The Amino-acid sequence homologies between selectins and B pertussis toxin-peptides derived therefrom antibodies thereto pharmaceutical compositions
US5891841A (en) * 1991-06-11 1999-04-06 The Center For Blood Research, Inc. Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
WO1993002702A1 (en) * 1991-07-31 1993-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Use of endothelial-leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma
GB9120768D0 (en) * 1991-09-30 1991-11-13 British Bio Technology Diagnostic and prognastic materials and methods
CA2120500A1 (en) * 1991-10-01 1993-04-15 Mitsuaki Isobe Preventing allograft rejection with antibodies to adhesion molecules
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
CA2107097A1 (en) * 1992-01-27 1993-07-28 Michael W. Gallatin Icam-related protein
US5773218A (en) * 1992-01-27 1998-06-30 Icos Corporation Method to identify compounds which modulate ICAM-related protein interactions
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP0627940B1 (de) * 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
NZ262615A (en) * 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
AU1280695A (en) * 1993-12-27 1995-07-17 Nisshin Oil Mills, Ltd., The Method of assaying complex formed between secretin and ligand thereof and use of said complex
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
WO1998026277A2 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6096511A (en) * 1997-06-10 2000-08-01 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
AU741017B2 (en) * 1997-06-10 2001-11-22 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
AU5541799A (en) 1998-03-31 1999-11-29 Du Pont Pharmaceuticals Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US20020160441A1 (en) * 1998-06-02 2002-10-31 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1140204A2 (de) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronektin-rezeptor antagonist arzeimittheln
US20030124132A1 (en) * 2001-09-27 2003-07-03 Board Of Regents, The University Of Texas System Combined compositions for tumor vasculature coaguligand treatment
CA3168704A1 (en) 2020-01-24 2021-07-29 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4727028A (en) * 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US4797277A (en) * 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1

Also Published As

Publication number Publication date
EP0534944B1 (de) 1996-09-11
US5403713A (en) 1995-04-04
ATE142505T1 (de) 1996-09-15
EP0534944A4 (de) 1991-09-23
JPH04501565A (ja) 1992-03-19
DE68927188D1 (de) 1996-10-17
WO1990005539A1 (en) 1990-05-31
EP0534944A1 (de) 1993-04-07
AU4621789A (en) 1990-06-12
CA2002860A1 (en) 1990-05-14
AU636589B2 (en) 1993-05-06

Similar Documents

Publication Publication Date Title
DE68927188T2 (de) Antikörper, spezifisch gegen elam-1 sowie deren verwendung
MX9203245A (es) Linea celular producida mediante una tecnica de hibridoma.
ES2182836T3 (es) Dispositivos de lectura para tiras de analisis.
ATE308754T1 (de) Effiziente anreicherung und detektion von ausgesäten tumorzellen
ES2037638T1 (es) Un metodo de generacion de luz.
DE19975008I2 (de) Kombination von Angiotensin-Converting-Enzyme-Hemmern mit Calciumantagonisten sowie deren Verwendungin Arzneimitteln.
DE399024T1 (de) Monoklonale antikoerper gegen interleukin-1 alpha und beta, deren herstellung und verwendung zum nachweis von interleukinen und fuer therapeutische zwecke.
ES8706182A1 (es) Procedimiento para la obtencion de un adhesivo para piezas moldeadas en pvc duro
DE3580927D1 (de) Die antigenischen determinanten von hbxag.
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
DE69631972D1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
IT8548600A0 (it) Pellicole sottili di polietilene ad alto peso molecolare,e procedimento per la loro preparazione
DE3585049D1 (de) Monoklonale antikoerper.
ATE103989T1 (de) Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
ES2001013A6 (es) Un metodo para la preparacion de anticuerpos especificos de histamina
DK0442372T3 (da) Forbedrede mærkede haptener, fremgangsmåde til deres fremstilling samt anvendelse af disse mærkede haptener ved immunoassays
DE69620814D1 (de) Monoklonäler Antikörper gegen die R2-Untereinheit von Ribonukleotid-Reduktase
ES8705232A1 (es) Un metodo para preparar un anticuerpo monoclonal destinado autilizarse como auxiliar de diagnostico para detectar cancerde pulmon
DE3786130D1 (de) Monoklonale antikoerper gegen oberflaechlichen ige-rezeptor, sowie hybrid-zellinien zu deren herstellung und verwendung.
DE3864645D1 (de) Langkettige n-alkyl-alpha-alkyl-nitrone sowie deren verwendung als stabilisatoren.
ES2018387A6 (es) Procedimiento de obtencion de un medicamento para inhibir la infeccion de celulas por virus hiv.
AU538833B2 (en) Method of diagnosing arterosclerosis
JP2000171467A5 (de)
McCartney Development of instrumentation for use with the 10 S 3. 5 KHz acoustic transponders fitted into experimental penetrators.
DE3854740T2 (de) Menschlicher monoklonaler antikörper gegen candida.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee